[Dose-effect relations. Doubleblind study on two different doses of pimozide (author's transl)]

Area of Science:

• Psychiatry and Pharmacology

Background:

• Schizophrenia treatment often involves antipsychotic medications.
• Pimozide is an antipsychotic medication used in managing schizophrenia.

Purpose of the Study:

• To compare the efficacy and side effect profiles of two different dosages of pimozide in schizophrenic patients.
• To determine the optimal dosage of pimozide for treating schizophrenia while minimizing adverse effects.

Main Methods:

• A randomized controlled trial involving two identical groups of schizophrenic patients.
• Patients were treated for 28 days with either 3 mg or 8 mg of pimozide.
• Antipsychotic efficacy and the occurrence of side effects, including extrapyramidal signs and need for tranquilizers, were monitored.

Main Results:

• No significant difference in antipsychotic efficacy was observed between the 3 mg and 8 mg pimozide groups.
• The 8 mg group experienced three times more extrapyramidal signs (akathisia, agitation) compared to the 3 mg group.
• The 8 mg group required seven times more minor tranquilizers than the 3 mg group.
• Severe agitation as a psychotic symptom was comparable in both dosage groups.

Conclusions:

• Lower dosage (3 mg) of pimozide demonstrates comparable efficacy to higher dosage (8 mg) in treating schizophrenia.
• The higher dosage (8 mg) is associated with a significantly increased risk of extrapyramidal side effects and greater need for adjunctive tranquilizers.
• The 3 mg dosage of pimozide is preferred due to a better side effect profile, offering a potentially safer treatment option for schizophrenia.